{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T12:10:25Z","timestamp":1789992625924,"version":"4.0.1"},"reference-count":190,"publisher":"Elsevier","isbn-type":[{"value":"9780443472183","type":"print"}],"license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/bs.irn.2026.08.019","type":"book-chapter","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T11:17:13Z","timestamp":1789039033000},"page":"75-112","source":"Crossref","is-referenced-by-count":0,"title":["Parkinson\u2019s disease\u2014Crucial advances and on-going challenges"],"prefix":"10.1016","author":[{"given":"Gra\u017cyna","family":"S\u00f6derbom","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/bs.irn.2026.08.019_bib1","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/j.1750-3639.2009.00369.x","article-title":"The epidemiology of dementia associated with Parkinson\u2019s disease","volume":"20","author":"Aarsland","year":"2010","journal-title":"Brain Pathology (Zurich, Switzerland)"},{"issue":"8","key":"10.1016\/bs.irn.2026.08.019_bib2","doi-asserted-by":"crossref","first-page":"4577","DOI":"10.1007\/s10787-025-01873-0","article-title":"Antidiabetic drugs in Parkinson\u2019s disease: A comprehensive meta-analysis on efficacy and safety with trial sequential analysis and grade evaluation","volume":"33","author":"Abou Elezz","year":"2025","journal-title":"Inflammopharmacology"},{"key":"10.1016\/bs.irn.2026.08.019_bib3","unstructured":"AC Immune SA. (2025). NCT06015841. A dtudy to evaluate the effects of ACI-7104.056 in patients with early stages of Parkinson\u2019s disease (VacSYn). Retrieved 20 June 2026 from https:\/\/clinicaltrials.gov\/study\/NCT06015841?term=ACI-7104&viewType=Card&rank=1."},{"issue":"3","key":"10.1016\/bs.irn.2026.08.019_bib4","article-title":"Mesenchymal stem cell therapy in Parkinson\u2019s disease: A comprehensive review","volume":"18","author":"Al Darmaki","year":"2026","journal-title":"Cureus"},{"key":"10.1016\/bs.irn.2026.08.019_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.parkreldis.2024.107220","article-title":"GLP-1 receptor agonists for Parkinson\u2019s disease: An updated meta-analysis","volume":"130","author":"Albuquerque","year":"2025","journal-title":"Parkinsonism & Related Disorders"},{"issue":"11","key":"10.1016\/bs.irn.2026.08.019_bib6","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26115405","article-title":"\u03b1-Synuclein pathology in synucleinopathies: Mechanisms, biomarkers, and therapeutic challenges","volume":"26","author":"Arias-Carri\u00f3n","year":"2025","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/bs.irn.2026.08.019_bib7","unstructured":"AstraZeneca. (2022). NCT04449484. Multiple ascending dose study of MEDI1341 in patients with Parkinson\u2019s disease. Retrieved 23 May 2026 from https:\/\/clinicaltrials.gov\/study\/NCT04449484?cond=MEDI1341&viewType=Card&rank=1."},{"issue":"5","key":"10.1016\/bs.irn.2026.08.019_bib8","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.drudis.2016.01.013","article-title":"The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson\u2019s disease: Mechanisms of action","volume":"21","author":"Athauda","year":"2016","journal-title":"Drug Discovery Today"},{"issue":"10103","key":"10.1016\/bs.irn.2026.08.019_bib9","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/S0140-6736(17)31585-4","article-title":"Exenatide once weekly versus placebo in Parkinson\u2019s disease: A randomised, double-blind, placebo-controlled trial","volume":"390","author":"Athauda","year":"2017","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/bs.irn.2026.08.019_bib10","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1136\/jnnp-2012-304436","article-title":"Clinical utility of dopamine transporter single photon emission CT (DaT-SPECT) with (123I) ioflupane in diagnosis of parkinsonian syndromes","volume":"84","author":"Bajaj","year":"2013","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"issue":"1","key":"10.1016\/bs.irn.2026.08.019_bib11","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.34890","article-title":"Allocation of national institutes of health funding by disease category in 2008 and 2019","volume":"4","author":"Ballreich","year":"2021","journal-title":"JAMA Network Open"},{"issue":"1","key":"10.1016\/bs.irn.2026.08.019_bib12","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s40478-021-01175-w","article-title":"Streamlined alpha-synuclein RT-QuIC assay for various biospecimens in Parkinson\u2019s disease and dementia with Lewy bodies","volume":"9","author":"Bargar","year":"2021","journal-title":"Acta Neuropathologica Communications"},{"issue":"16","key":"10.1016\/bs.irn.2026.08.019_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/cells14161272","article-title":"Current status of \u03b1-synuclein biomarkers and the need for \u03b1-synuclein PET tracers","volume":"14","author":"Berman","year":"2025","journal-title":"Cells"},{"key":"10.1016\/bs.irn.2026.08.019_bib14","unstructured":"Biogen. (2025). NCT03318523. Evaluating the efficacy, safety, pharmacokinetics, and pharmacodynamics of biib054 in participants with Parkinson\u2019s disease (SPARK). Retrieved 23 May 2026 from https:\/\/clinicaltrials.gov\/search?cond=NCT03318523&viewType=Card."},{"issue":"1","key":"10.1016\/bs.irn.2026.08.019_bib15","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41531-025-01199-2","article-title":"Spatial single-cell multiomics reveals peripheral immune dysfunction in Parkinson\u2019s and inflammatory bowel disease","volume":"12","author":"Bolen","year":"2026","journal-title":"npj Parkinson\u2019s Disease"},{"issue":"s1","key":"10.1016\/bs.irn.2026.08.019_bib16","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.3233\/JPD-179001","article-title":"Neuropathological staging of brain pathology in sporadic Parkinson\u2019s disease: Separating the wheat from the chaff","volume":"7","author":"Braak","year":"2017","journal-title":"npj Parkinson\u2019s Disease"},{"issue":"10","key":"10.1016\/bs.irn.2026.08.019_bib17","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1093\/brain\/awaa262","article-title":"Diabetes medications and risk of Parkinson\u2019s disease: A cohort study of patients with diabetes","volume":"143","author":"Brauer","year":"2020","journal-title":"Brain"},{"issue":"1","key":"10.1016\/bs.irn.2026.08.019_bib18","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41531-025-01221-7","article-title":"Quantification of cerebrospinal fluid \u03b1-synuclein seeds by endpoint dilution seed amplification assay in Parkinson\u2019s disease","volume":"12","author":"Brockmann","year":"2025","journal-title":"npj Parkinson\u2019s Disease"},{"issue":"5","key":"10.1016\/bs.irn.2026.08.019_bib19","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1002\/mds.70197","article-title":"Clinical and imaging characteristics of Parkinson\u2019s disease with negative alpha-synuclein seed amplification assay","volume":"41","author":"Brooker","year":"2026","journal-title":"Movement Disorders: Official Journal of the Movement Disorder Society"},{"issue":"6","key":"10.1016\/bs.irn.2026.08.019_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0326568","article-title":"Seeding amplification assay with universal control fluid: Standardized detection of \u03b1-synucleinopathies","volume":"20","author":"Bsoul","year":"2025","journal-title":"PLoS One"},{"key":"10.1016\/bs.irn.2026.08.019_bib21","doi-asserted-by":"crossref","DOI":"10.1177\/1877718X261454154","article-title":"Parkinson\u2019s disease drug therapies in the clinical trial pipeline: 2015-2024","author":"Buff","year":"2026","journal-title":"npj Parkinson\u2019s Disease"},{"issue":"5","key":"10.1016\/bs.irn.2026.08.019_bib22","doi-asserted-by":"crossref","DOI":"10.3390\/ijms27052194","article-title":"The progress of active immunotherapy for Parkinson\u2019s disease","volume":"27","author":"Busot","year":"2026","journal-title":"International Journal of Molecular Sciences"},{"issue":"6","key":"10.1016\/bs.irn.2026.08.019_bib23","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1002\/mds.29784","article-title":"Randomized phase I trial of the \u03b1-synuclein antibody Lu AF82422","volume":"39","author":"Buur","year":"2024","journal-title":"Movement Disorders: Official Journal of the Movement Disorder Society"},{"issue":"3","key":"10.1016\/bs.irn.2026.08.019_bib24","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s41419-023-05672-9","article-title":"Alpha-synuclein in Parkinson\u2019s disease and other synucleinopathies: From overt neurodegeneration back to early synaptic dysfunction","volume":"14","author":"Calabresi","year":"2023","journal-title":"Cell Death and Disease"},{"issue":"1","key":"10.1016\/bs.irn.2026.08.019_bib25","doi-asserted-by":"crossref","DOI":"10.3390\/cells15010042","article-title":"Non-motor symptoms: The hidden face of Parkinson\u2019s disease","volume":"15","author":"Cattaneo","year":"2025","journal-title":"Cells"},{"key":"10.1016\/bs.irn.2026.08.019_bib26","unstructured":"Cedars-Sinai Medical Center. (2024). NCT02953665. Safety and efficacy of liraglutide in Parkinson\u2019s disease. Retrieved 25 May 2026 from https:\/\/clinicaltrials.gov\/study\/NCT02953665?cond=Liraglutide%20&term=parkinson%27s&viewType=Card&rank=1."},{"issue":"5","key":"10.1016\/bs.irn.2026.08.019_bib27","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1002\/acn3.51753","article-title":"Central and peripheral \u03b1-synuclein in Parkinson disease detected by seed amplification assay","volume":"10","author":"Chahine","year":"2023","journal-title":"Annals of Clinical and Translational Neurology"},{"issue":"5","key":"10.1016\/bs.irn.2026.08.019_bib28","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/s41419-023-05835-8","article-title":"Tunnelling nanotubes between neuronal and microglial cells allow bi-directional transfer of \u03b1-Synuclein and mitochondria","volume":"14","author":"Chakraborty","year":"2023","journal-title":"Cell Death & Disease"},{"issue":"7","key":"10.1016\/bs.irn.2026.08.019_bib29","doi-asserted-by":"crossref","first-page":"395","DOI":"10.3349\/ymj.2024.0447","article-title":"Human pluripotent stem cell-based therapies for Parkinson\u2019s disease: Challenges and potential solutions","volume":"66","author":"Chang","year":"2025","journal-title":"Yonsei Medical Journal"},{"key":"10.1016\/bs.irn.2026.08.019_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2025.1617106","article-title":"Understanding Parkinson\u2019s disease: Current trends and its multifaceted complications","volume":"17","author":"Chaudhary","year":"2025","journal-title":"Frontiers in Aging Neuroscience"},{"issue":"1","key":"10.1016\/bs.irn.2026.08.019_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40801-023-00410-1","article-title":"Economic burden of Parkinson\u2019s disease: A multinational, real-world, cost-of-illness study","volume":"11","author":"Chaudhuri","year":"2024","journal-title":"Drugs Real World Outcomes"},{"issue":"8","key":"10.1016\/bs.irn.2026.08.019_bib32","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24087205","article-title":"Gut-to-brain \u03b1-synuclein transmission in Parkinson\u2019s disease: Evidence for prion-like mechanisms","volume":"24","author":"Chen","year":"2023","journal-title":"International Journal of Molecular Sciences"},{"issue":"6","key":"10.1016\/bs.irn.2026.08.019_bib33","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/ana.21995","article-title":"Clinical progression in Parkinson disease and the neurobiology of axons","volume":"67","author":"Cheng","year":"2010","journal-title":"Annals of Neurology"},{"issue":"10","key":"10.1016\/bs.irn.2026.08.019_bib34","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1002\/mds.30307","article-title":"Anti-neuroinflammatory and anti-inflammatory effects of the NLRP3 Inhibitor NT-0796 in subjects with Parkinson\u2019s disease","volume":"40","author":"Clarke","year":"2025","journal-title":"Movement Disorders: Official Journal of the Movement Disorder Society"},{"issue":"1","key":"10.1016\/bs.irn.2026.08.019_bib35","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/s41531-024-00789-w","article-title":"Neuronal alpha-synuclein disease integrated staging system performance in PPMI, PASADENA, and SPARK baseline cohorts","volume":"10","author":"Dam","year":"2024","journal-title":"NPJ Parkinson\u2019s Disease"},{"issue":"2","key":"10.1016\/bs.irn.2026.08.019_bib36","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1212\/WNL.0000000000005771","article-title":"Association between diabetes and subsequent Parkinson disease: A record-linkage cohort study","volume":"91","author":"De Pablo-Fernandez","year":"2018","journal-title":"Neurology"},{"issue":"15","key":"10.1016\/bs.irn.2026.08.019_bib37","first-page":"412","article-title":"The treatment of older patients with Parkinson\u2019s disease","volume":"122","author":"Djukic","year":"2025","journal-title":"Deutsches \u00c4rzteblatt International"},{"issue":"3","key":"10.1016\/bs.irn.2026.08.019_bib38","first-page":"451","article-title":"Parkinson\u2019s disease is predominantly an environmental disease","volume":"14","author":"Dorsey","year":"2024","journal-title":"Deutsches \u00c4rzteblatt International"},{"issue":"s1","key":"10.1016\/bs.irn.2026.08.019_bib39","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.3233\/JPD-181474","article-title":"The emerging evidence of the Parkinson pandemic","volume":"8","author":"Dorsey","year":"2018","journal-title":"Journal of Parkinson\u2019s Disease"},{"issue":"1","key":"10.1016\/bs.irn.2026.08.019_bib40","first-page":"171","article-title":"The value of PET\/CT in the diagnosis and differential diagnosis of Parkinson\u2019s disease: A dual-tracer study","volume":"10","author":"Du","year":"2024","journal-title":"Journal of Parkinson\u2019s Disease"},{"issue":"12","key":"10.1016\/bs.irn.2026.08.019_bib41","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1001\/jamaneurol.2024.3770","article-title":"Alzheimer disease as a clinical-biological construct-an international working group recommendation","volume":"81","author":"Dubois","year":"2024","journal-title":"JAMA Neurology"},{"issue":"9","key":"10.1016\/bs.irn.2026.08.019_bib42","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1038\/s41591-024-03101-8","article-title":"Target engagement and immunogenicity of an active immunotherapeutic targeting pathological \u03b1-synuclein: A phase 1 placebo-controlled trial","volume":"30","author":"Eijsvogel","year":"2024","journal-title":"Nature Medicine"},{"key":"10.1016\/bs.irn.2026.08.019_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.parkreldis.2024.107256","article-title":"The \u03b1-synuclein seed amplification assay: Interpreting a test of Parkinson\u2019s pathology","volume":"131","author":"Espay","year":"2025","journal-title":"Parkinsonism & Related Disorders"},{"issue":"10","key":"10.1016\/bs.irn.2026.08.019_bib44","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1002\/acn3.338","article-title":"Alpha-synuclein RT-QuIC in the CSF of patients with alpha-synucleinopathies","volume":"3","author":"Fairfoul","year":"2016","journal-title":"Annals of Clinical and Translational Neurology"},{"issue":"1","key":"10.1016\/bs.irn.2026.08.019_bib45","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12974-019-1670-6","article-title":"Systemic activation of NLRP3 inflammasome and plasma \u03b1-synuclein levels are correlated with motor severity and progression in Parkinson\u2019s disease","volume":"17","author":"Fan","year":"2020","journal-title":"Journal of Neuroinflammation"},{"issue":"2","key":"10.1016\/bs.irn.2026.08.019_bib46","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/ane.13648","article-title":"Intercountry comparisons of advanced Parkinson\u2019s disease symptoms and management: Analysis from the OBSERVE-PD observational study","volume":"146","author":"Fasano","year":"2022","journal-title":"Acta Neurologica Scandinavica"},{"issue":"Pt 5","key":"10.1016\/bs.irn.2026.08.019_bib47","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1093\/brain\/114.5.2283","article-title":"Ageing and Parkinson\u2019s disease: Substantia nigra regional selectivity","volume":"114","author":"Fearnley","year":"1991","journal-title":"Brain"},{"key":"10.1016\/bs.irn.2026.08.019_bib48","doi-asserted-by":"crossref","DOI":"10.1177\/1877718X261420002","article-title":"Evolution of disease modifying therapy clinical trial design and therapeutic endpoints for Parkinson\u2019s disease","author":"Foltynie","year":"2026","journal-title":"Journal of Parkinson\u2019s Disease"},{"issue":"10510","key":"10.1016\/bs.irn.2026.08.019_bib49","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1016\/S0140-6736(25)01389-3","article-title":"Alzheimer\u2019s disease outlook: Controversies and future directions","volume":"406","author":"Frisoni","year":"2025","journal-title":"Lancet"},{"issue":"10510","key":"10.1016\/bs.irn.2026.08.019_bib50","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S0140-6736(25)01294-2","article-title":"New landscape of the diagnosis of Alzheimer\u2019s disease","volume":"406","author":"Frisoni","year":"2025","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/bs.irn.2026.08.019_bib51","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1136\/jnnp.51.6.745","article-title":"The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson\u2019s disease","volume":"51","author":"Gibb","year":"1988","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"issue":"2","key":"10.1016\/bs.irn.2026.08.019_bib52","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s40263-018-0601-x","article-title":"Novel treatment opportunities against cognitive impairment in Parkinson\u2019s disease with an emphasis on diabetes-related pathways","volume":"33","author":"Green","year":"2019","journal-title":"CNS Drugs"},{"issue":"4","key":"10.1016\/bs.irn.2026.08.019_bib53","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1001\/archneur.63.4.584","article-title":"Motor score of the Unified Parkinson disease rating scale as a good predictor of lewy body-associated neuronal loss in the substantia nigra","volume":"63","author":"Greffard","year":"2006","journal-title":"Archives of Neurology"},{"issue":"1","key":"10.1016\/bs.irn.2026.08.019_bib54","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2023.2261509","article-title":"Delivery of the brainshuttle\u2122 amyloid-beta antibody fusion trontinemab to non-human primate brain and projected efficacious dose regimens in humans","volume":"15","author":"Grimm","year":"2023","journal-title":"MAbs"},{"key":"10.1016\/bs.irn.2026.08.019_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2024.102192","article-title":"Passive immunotherapy for Alzheimer\u2019s disease","volume":"94","author":"Guo","year":"2024","journal-title":"Ageing Research Reviews"},{"issue":"2-3","key":"10.1016\/bs.irn.2026.08.019_bib56","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1159\/000511083","article-title":"Alpha-synuclein: The interplay of pathology, neuroinflammation, and environmental factors in Parkinson\u2019s disease","volume":"20","author":"He","year":"2020","journal-title":"Neuro-degenerative Diseases"},{"issue":"1","key":"10.1016\/bs.irn.2026.08.019_bib57","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1186\/s13098-025-01888-1","article-title":"GLP-1 receptor agonists in Parkinson\u2019s disease: An updated comprehensive systematic review with meta-analysis","volume":"17","author":"Helal","year":"2025","journal-title":"Diabetology & Metabolic Syndrome"},{"key":"10.1016\/bs.irn.2026.08.019_bib58","unstructured":"Hoffmann-La Roche. (2026a). NCT07170150. A clinical trial of trontinemab in participants with early symptomatic Alzheimer\u2019s disease (TRONTIER 2). Retrieved 23 May 2026 from https:\/\/clinicaltrials.gov\/study\/NCT07170150?cond=Trontinemab%20&viewType=Card&rank=2."},{"key":"10.1016\/bs.irn.2026.08.019_bib59","unstructured":"Hoffmann-La Roche. (2026b). NCT07169578. A study of trontinemab in participants with early symptomatic Alzheimer\u2019s disease (TRONTIER 1). Retrieved 23 May 2026 from https:\/\/clinicaltrials.gov\/study\/NCT07169578?cond=Trontinemab%20&viewType=Card&rank=1."},{"key":"10.1016\/bs.irn.2026.08.019_bib60","unstructured":"Hoffmann-La Roche. (2026c). NCT07174310. A study to evaluate the efficacy and safety of intravenous (IV) prasinezumab in participants with early-stage Parkinson\u2019s disease (PARAISO). Retrieved 25 May 2026 from https:\/\/clinicaltrials.gov\/study\/NCT07174310."},{"key":"10.1016\/bs.irn.2026.08.019_bib61","unstructured":"Hoffmann-La Roche. (2026d). NCT04777331. A study to evaluate the efficacy and safety of intravenous prasinezumab in participants with early Parkinson\u2019s disease (PADOVA). Retrieved 23 May 2026 from https:\/\/clinicaltrials.gov\/study\/NCT04777331?cond=NCT04777331&viewType=Card&rank=1."},{"key":"10.1016\/bs.irn.2026.08.019_bib62","unstructured":"Hoffmann-La Roche. (2026e). NCT03100149. A study to evaluate the efficacy of prasinezumab (RO7046015\/PRX002) in participants with early Parkinson\u2019s disease (PASADENA). Retrieved 23 May 2026 from https:\/\/clinicaltrials.gov\/search?cond=NCT03100149&viewType=Card."},{"key":"10.1016\/bs.irn.2026.08.019_bib63","unstructured":"Hoffmann-La Roche. (2026f). NCT05924243. A study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of RO7486967 in participants with early idiopathic Parkinson\u2019s disease. Retrieved 25 May 2026 from https:\/\/clinicaltrials.gov\/study\/NCT05924243?cond=NCT05924243&viewType=Card&rank=1."},{"issue":"5","key":"10.1016\/bs.irn.2026.08.019_bib64","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1177\/1877718X241298194","article-title":"SynNeurGe: The road ahead for a biological definition of Parkinson\u2019s disease","volume":"15","author":"H\u00f6glinger","year":"2025","journal-title":"Journal of Parkinson\u2019s Disease"},{"issue":"2","key":"10.1016\/bs.irn.2026.08.019_bib65","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S1474-4422(23)00404-0","article-title":"A biological classification of Parkinson\u2019s disease: The SynNeurGe research diagnostic criteria","volume":"23","author":"H\u00f6glinger","year":"2024","journal-title":"Lancet Neurology"},{"issue":"1-2","key":"10.1016\/bs.irn.2026.08.019_bib66","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0891-0618(01)00100-4","article-title":"Chemical neuroanatomy of the basal ganglia--normal and in Parkinson\u2019s disease","volume":"22","author":"Hornykiewicz","year":"2001","journal-title":"Journal of Chemical Neuroanatomy"},{"key":"10.1016\/bs.irn.2026.08.019_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.parkreldis.2024.106101","article-title":"Brain-first vs. body-first Parkinson\u2019s disease: An update on recent evidence","volume":"122","author":"Horsager","year":"2024","journal-title":"Parkinsonism & Related Disorders"},{"issue":"3","key":"10.1016\/bs.irn.2026.08.019_bib68","doi-asserted-by":"crossref","first-page":"208","DOI":"10.5582\/ddt.2025.01055","article-title":"The pTau217\/A\u03b2(1-42) plasma ratio: The first FDA-cleared blood biomarker test for diagnosis of Alzheimer\u2019s disease","volume":"19","author":"Hu","year":"2025","journal-title":"Drug Discoveries & Therapeutics"},{"issue":"1","key":"10.1016\/bs.irn.2026.08.019_bib69","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1038\/s41467-023-38248-4","article-title":"Gut microbiome dysbiosis across early Parkinson\u2019s disease, REM sleep behavior disorder and their first-degree relatives","volume":"14","author":"Huang","year":"2023","journal-title":"Nature Communications"},{"key":"10.1016\/bs.irn.2026.08.019_bib70","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2021.615075","article-title":"Review: The role of intestinal dysbiosis in Parkinson\u2019s disease","volume":"11","author":"Huang","year":"2021","journal-title":"Frontiers in Cellular and Infection Microbiology"},{"issue":"1","key":"10.1016\/bs.irn.2026.08.019_bib71","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1186\/s12883-021-02470-8","article-title":"Evaluating dopamine transporter imaging as an enrichment biomarker in a phase 2 Parkinson\u2019s disease trial","volume":"21","author":"Hutchison","year":"2021","journal-title":"BMC Neurology"},{"issue":"5","key":"10.1016\/bs.irn.2026.08.019_bib72","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209137","article-title":"Cinpanemab in early Parkinson disease: Evaluation of biomarker results from the phase 2 SPARK clinical trial","volume":"102","author":"Hutchison","year":"2024","journal-title":"Neurology"},{"key":"10.1016\/bs.irn.2026.08.019_bib73","unstructured":"ISRCTN. (2024). ISRCTN85338453. A study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of selnofast in participants with early idiopathic Parkinson\u2019s disease. Retrieved 25 May 2026 from https:\/\/www.isrctn.com\/ISRCTN85338453."},{"issue":"4","key":"10.1016\/bs.irn.2026.08.019_bib74","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA research framework: Toward a biological definition of Alzheimer\u2019s disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimer\u2019s & Dementia: the Journal of the Alzheimer\u2019s Association"},{"key":"10.1016\/bs.irn.2026.08.019_bib75","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2021.765765","article-title":"Hoehn and Yahr stage and striatal Dat-SPECT uptake are predictors of Parkinson\u2019s disease motor progression","volume":"15","author":"Jackson","year":"2021","journal-title":"Frontiers in Neuroscience"},{"issue":"4","key":"10.1016\/bs.irn.2026.08.019_bib76","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1136\/jnnp.2007.131045","article-title":"Parkinson\u2019s disease: Clinical features and diagnosis","volume":"79","author":"Jankovic","year":"2008","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"issue":"1-2","key":"10.1016\/bs.irn.2026.08.019_bib77","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jns.2011.04.012","article-title":"Synuclein deposition and non-motor symptoms in Parkinson disease","volume":"310","author":"Jellinger","year":"2011","journal-title":"Journal of the Neurological Sciences"},{"issue":"2","key":"10.1016\/bs.irn.2026.08.019_bib78","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s00702-025-03006-x","article-title":"COMT inhibition with entacapone for patients with Parkinson\u2019s disease and motor complications: The novelty of continuous infusion","volume":"133","author":"Jenner","year":"2026","journal-title":"Journal of Neural Transmission\u00a0(Vienna)"},{"issue":"2","key":"10.1016\/bs.irn.2026.08.019_bib79","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/mds.27922","article-title":"Body mass index, diabetes, and the risk of Parkinson\u2019s disease","volume":"35","author":"Jeong","year":"2020","journal-title":"Movement Disorders: Official Journal of the Movement Disorder Society"},{"issue":"7","key":"10.1016\/bs.irn.2026.08.019_bib80","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.70659","article-title":"The evolving global burden of Young-Onset Parkinson\u2019s disease (1990-2021): Regional, gender, and age disparities in the context of rising incidence and declining mortality","volume":"15","author":"Jiang","year":"2025","journal-title":"Brain and Behavior"},{"issue":"1","key":"10.1016\/bs.irn.2026.08.019_bib81","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/s41531-024-00849-1","article-title":"Rational selection of the monoclonal \u03b1-synuclein antibody amlenetug (Lu AF82422) for the treatment of \u03b1-synucleinopathies","volume":"11","author":"Kallunki","year":"2025","journal-title":"npj Parkinson\u2019s Disease"},{"issue":"1","key":"10.1016\/bs.irn.2026.08.019_bib82","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcad002","article-title":"Genetic overlap between Parkinson\u2019s disease and inflammatory bowel disease","volume":"5","author":"Kang","year":"2023","journal-title":"Brain Communications"},{"key":"10.1016\/bs.irn.2026.08.019_bib83","article-title":"Longitudinal DAT changes measured with [(18)F]FE-PE2I PET in patients with Parkinson\u2019s disease; a validation study","volume":"37","author":"Kerstens","year":"2023","journal-title":"NeuroImage: Clinical"},{"issue":"6","key":"10.1016\/bs.irn.2026.08.019_bib84","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1002\/ana.26917","article-title":"\u03b1-Synuclein pathology in PRKN-linked Parkinson\u2019s disease: New insights from a blood-based seed amplification assay","volume":"95","author":"Kluge","year":"2024","journal-title":"Annals of Neurology"},{"issue":"8","key":"10.1016\/bs.irn.2026.08.019_bib85","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1002\/mds.29766","article-title":"Detecting misfolded \u03b1-synuclein in blood years before the diagnosis of Parkinson\u2019s disease","volume":"39","author":"Kluge","year":"2024","journal-title":"Movement Disorders: Official Journal of the Movement Disorder Society"},{"key":"10.1016\/bs.irn.2026.08.019_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106550","article-title":"Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: Implications for neurodegenerative disease treatment","volume":"186","author":"Kopp","year":"2022","journal-title":"Pharmacological Research: the Official Journal of the Italian Pharmacological Society"},{"issue":"5","key":"10.1016\/bs.irn.2026.08.019_bib87","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nm1747","article-title":"Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson\u2019s disease","volume":"14","author":"Kordower","year":"2008","journal-title":"Nature Medicine"},{"issue":"Pt 8","key":"10.1016\/bs.irn.2026.08.019_bib88","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1093\/brain\/awt192","article-title":"Disease duration and the integrity of the nigrostriatal system in Parkinson\u2019s disease","volume":"136","author":"Kordower","year":"2013","journal-title":"Brain"},{"issue":"2","key":"10.1016\/bs.irn.2026.08.019_bib89","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/ng0298-106","article-title":"Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson\u2019s disease","volume":"18","author":"Kr\u00fcger","year":"1998","journal-title":"Nature Genetics"},{"issue":"1","key":"10.1016\/bs.irn.2026.08.019_bib90","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s40035-025-00488-3","article-title":"Enhanced serum-based seed amplification assay for detecting propagative \u03b1-synuclein seeds in Parkinson\u2019s disease","volume":"14","author":"Kuang","year":"2025","journal-title":"Translational Neurodegeneration"},{"issue":"6","key":"10.1016\/bs.irn.2026.08.019_bib91","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1007\/s00259-020-05133-x","article-title":"[(11)C]MODAG-001-towards a PET tracer targeting \u03b1-synuclein aggregates","volume":"48","author":"Kuebler","year":"2021","journal-title":"European Journal of Nuclear Medicine and Molecular Imaging"},{"key":"10.1016\/bs.irn.2026.08.019_bib92","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp-2022-abn2.97","article-title":"Brainshuttle AD: Investigating safety, tolerability, and PK\/PD of RG6102 in prodromal\/mild-to-moderate AD. Abstract 053","volume":"93","author":"Kulic","year":"2022","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"issue":"5","key":"10.1016\/bs.irn.2026.08.019_bib93","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa2203395","article-title":"Trial of cinpanemab in early Parkinson\u2019s disease","volume":"387","author":"Lang","year":"2022","journal-title":"The New England Journal of Medicine"},{"issue":"21","key":"10.1016\/bs.irn.2026.08.019_bib94","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1093\/eurheartj\/ehab922","article-title":"Effect of a multi-domain lifestyle intervention on cardiovascular risk in older people: The FINGER trial","volume":"43","author":"Lehtisalo","year":"2022","journal-title":"European Heart Journal"},{"issue":"5","key":"10.1016\/bs.irn.2026.08.019_bib95","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1111\/ene.15734","article-title":"Gastrointestinal barriers to levodopa transport and absorption in Parkinson\u2019s disease","volume":"30","author":"Leta","year":"2023","journal-title":"European Journal of Neurology: the Official Journal of the European Federation of Neurological Societies"},{"issue":"3","key":"10.1016\/bs.irn.2026.08.019_bib96","doi-asserted-by":"crossref","DOI":"10.1002\/alz.14528","article-title":"Considerations in the clinical use of amyloid PET and CSF biomarkers for Alzheimer\u2019s disease","volume":"21","author":"Leuzy","year":"2025","journal-title":"Alzheimer\u2019s & Dementia: the Journal of the Alzheimer\u2019s Association"},{"issue":"5","key":"10.1016\/bs.irn.2026.08.019_bib97","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/nm1746","article-title":"Lewy bodies in grafted neurons in subjects with Parkinson\u2019s disease suggest host-to-graft disease propagation","volume":"14","author":"Li","year":"2008","journal-title":"Nature Medicine"},{"key":"10.1016\/bs.irn.2026.08.019_bib98","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2025.1495769","article-title":"Early diagnosis of Parkinson\u2019s disease: Biomarker study","volume":"17","author":"Li","year":"2025","journal-title":"Frontiers in Aging Neuroscience"},{"issue":"14","key":"10.1016\/bs.irn.2026.08.019_bib99","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000019662","article-title":"Positron emission tomography\/computed tomography dual imaging using 18-fluorine flurodeoxyglucose and 11C-labeled 2-\u03b2-carbomethoxy-3-\u03b2-(4-fluorophenyl) tropane for the severity assessment of Parkinson disease","volume":"99","author":"Li","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/bs.irn.2026.08.019_bib100","article-title":"Mapping the global burden of early-onset Parkinson\u2019s disease: Socioeconomic and regional inequalities from the Global Burden of Disease Study 2021","volume":"13","author":"Li","year":"2025","journal-title":"Frontiers in Public Health"},{"issue":"1","key":"10.1016\/bs.irn.2026.08.019_bib101","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0022-510X(97)00100-7","article-title":"Correlation between neuromorphometry in the substantia nigra and clinical features in Parkinson\u2019s disease using disector counts","volume":"151","author":"Ma","year":"1997","journal-title":"Journal of the Neurological Sciences"},{"issue":"12","key":"10.1016\/bs.irn.2026.08.019_bib102","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/S1474-4422(24)00395-8","article-title":"Sensitivity and specificity of a seed amplification assay for diagnosis of multiple system atrophy: A multicentre cohort study","volume":"23","author":"Ma","year":"2024","journal-title":"Lancet Neurology"},{"issue":"2","key":"10.1016\/bs.irn.2026.08.019_bib103","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00415-026-13615-5","article-title":"Three years later: Tracking bothersome symptoms and impacts for people with early Parkinson\u2019s disease","volume":"273","author":"Mammen","year":"2026","journal-title":"Journal of Neurology"},{"key":"10.1016\/bs.irn.2026.08.019_bib104","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2025.105567","article-title":"Evidence for alpha-synuclein aggregation in older individuals with hyposmia: A cross-sectional study","volume":"112","author":"Marek","year":"2025","journal-title":"EBioMedicine"},{"issue":"4","key":"10.1016\/bs.irn.2026.08.019_bib105","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.jamda.2017.09.020","article-title":"The effect of a 2-year intervention consisting of diet, physical exercise, cognitive training, and monitoring of vascular risk on chronic morbidity-the FINGER randomized controlled trial","volume":"19","author":"Marengoni","year":"2018","journal-title":"Journal of the American Medical Directors Association"},{"issue":"1","key":"10.1016\/bs.irn.2026.08.019_bib106","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13024-025-00827-y","article-title":"Immune cell metabolic dysfunction in Parkinson\u2019s disease","volume":"20","author":"Mark","year":"2025","journal-title":"Molecular Neurodegeneration"},{"key":"10.1016\/bs.irn.2026.08.019_bib107","doi-asserted-by":"crossref","DOI":"10.1002\/mds.70324","article-title":"Co- and multi-pathologies in Parkinson\u2019s disease: An International Parkinson and movement disorder society scientific issues committee review","author":"Matarazzo","year":"2026","journal-title":"Movement Disorders: Official Journal of the Movement Disorder Society"},{"issue":"8","key":"10.1016\/bs.irn.2026.08.019_bib108","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.3233\/JPD-229007","article-title":"Prasinezumab and cinpanemab - the perspective of a person with Parkinson\u2019s","volume":"12","author":"McFarthing","year":"2022","journal-title":"Journal of Parkinson\u2019s Disease"},{"issue":"5","key":"10.1016\/bs.irn.2026.08.019_bib109","doi-asserted-by":"crossref","first-page":"899","DOI":"10.3233\/JPD-240272","article-title":"Parkinson\u2019s disease drug therapies in the clinical trial pipeline: 2024 update","volume":"14","author":"McFarthing","year":"2024","journal-title":"Journal of Parkinson\u2019s Disease"},{"key":"10.1016\/bs.irn.2026.08.019_bib110","article-title":"What medicines do people with Parkinson\u2019s disease want?","author":"McFarthing","year":"2025","journal-title":"Journal of Parkinson\u2019s Disease"},{"issue":"1","key":"10.1016\/bs.irn.2026.08.019_bib111","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S1474-4422(23)00378-2","article-title":"Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled trial","volume":"23","author":"McGarry","year":"2024","journal-title":"Lancet Neurology"},{"issue":"13","key":"10.1016\/bs.irn.2026.08.019_bib112","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1056\/NEJMoa2312323","article-title":"Trial of lixisenatide in early Parkinson\u2019s disease","volume":"390","author":"Meissner","year":"2024","journal-title":"The New England Journal of Medicine"},{"issue":"6","key":"10.1016\/bs.irn.2026.08.019_bib113","doi-asserted-by":"crossref","DOI":"10.1007\/s10072-026-09084-3","article-title":"Efficacy and safety of GLP-1 receptor agonists in Parkinson\u2019s disease: A systematic review and meta-analysis of randomized clinical trials","volume":"47","author":"Mendon\u00e7a","year":"2026","journal-title":"Neurological Sciences: Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology"},{"issue":"1","key":"10.1016\/bs.irn.2026.08.019_bib114","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41531-023-00457-5","article-title":"Peripheral inflammatory immune response differs among sporadic and familial Parkinson\u2019s disease","volume":"9","author":"Mu\u00f1oz-Delgado","year":"2023","journal-title":"npj Parkinson\u2019s Disease"},{"issue":"1","key":"10.1016\/bs.irn.2026.08.019_bib115","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13024-024-00766-0","article-title":"Gut-first Parkinson\u2019s disease is encoded by gut dysbiome","volume":"19","author":"Munoz-Pinto","year":"2024","journal-title":"Molecular Neurodegeneration"},{"key":"10.1016\/bs.irn.2026.08.019_bib116","unstructured":"Neuraly Inc. (2026). NCT04154072. A clinical study of NLY01 in Patient\u2019s with early Parkinson\u2019s disease. Retrieved 25 May 2026 from https:\/\/clinicaltrials.gov\/study\/NCT04154072?cond=NCT04154072&viewType=Card&rank=1."},{"issue":"9984","key":"10.1016\/bs.irn.2026.08.019_bib117","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1016\/S0140-6736(15)60461-5","article-title":"A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): A randomised controlled trial","volume":"385","author":"Ngandu","year":"2015","journal-title":"Lancet"},{"issue":"10544","key":"10.1016\/bs.irn.2026.08.019_bib118","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1016\/S0140-6736(26)00865-2","article-title":"Efficacy and safety of intravenous prasinezumab in individuals with early-stage Parkinson\u2019s disease on stable symptomatic monotherapy (PADOVA): A phase 2b, multicentre, randomised, double-blind, placebo-controlled study","volume":"407","author":"Nikolcheva","year":"2026","journal-title":"Lancet"},{"key":"10.1016\/bs.irn.2026.08.019_bib119","doi-asserted-by":"crossref","DOI":"10.1016\/j.parkreldis.2024.107257","article-title":"A Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of intravenous prasinezumab in early-stage Parkinson\u2019s disease (PADOVA): Rationale, design, and baseline data","volume":"132","author":"Nikolcheva","year":"2025","journal-title":"Parkinsonism & Related Disorders"},{"key":"10.1016\/bs.irn.2026.08.019_bib120","unstructured":"NYU Langone Health. (2026). NCT05634876. UB-312 in patients with synucleinopathies. Retrieved 20 May 2026 from https:\/\/clinicaltrials.gov\/study\/NCT05634876?term=UB-312&viewType=Card&rank=2."},{"key":"10.1016\/bs.irn.2026.08.019_bib121","doi-asserted-by":"crossref","DOI":"10.1177\/1877718X261431949","article-title":"Collaborative action for biomarker breakthroughs: Validating \u03b1-synuclein seed amplification assays in Parkinson\u2019s disease","author":"Oliveira","year":"2026","journal-title":"Journal of Parkinson\u2019s Disease"},{"key":"10.1016\/bs.irn.2026.08.019_bib122","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.705407","article-title":"A phase II study to evaluate the safety and efficacy of prasinezumab in early Parkinson\u2019s disease (PASADENA): Rationale, design, and baseline data","volume":"12","author":"Pagano","year":"2021","journal-title":"Frontiers in Neurology"},{"issue":"1","key":"10.1016\/bs.irn.2026.08.019_bib123","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/s41531-024-00845-5","article-title":"Biologically defined neuronal synuclein disease as a tool to advance drug development","volume":"10","author":"Pagano","year":"2024","journal-title":"NPJ Parkinson\u2019s Disease"},{"issue":"12","key":"10.1016\/bs.irn.2026.08.019_bib124","doi-asserted-by":"crossref","first-page":"3669","DOI":"10.1038\/s41591-024-03270-6","article-title":"Sustained effect of prasinezumab on Parkinson\u2019s disease motor progression in the open-label extension of the PASADENA trial","volume":"30","author":"Pagano","year":"2024","journal-title":"Nature Medicine"},{"issue":"4","key":"10.1016\/bs.irn.2026.08.019_bib125","first-page":"371","article-title":"Imaging in Parkinson\u2019s disease","volume":"16","author":"Pagano","year":"2016","journal-title":"Clinical Medicine\u00a0(London)"},{"issue":"4","key":"10.1016\/bs.irn.2026.08.019_bib126","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/s41591-024-02886-y","article-title":"Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson\u2019s disease","volume":"30","author":"Pagano","year":"2024","journal-title":"Nature Medicine"},{"issue":"5","key":"10.1016\/bs.irn.2026.08.019_bib127","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1056\/NEJMoa2202867","article-title":"Trial of prasinezumab in early-stage Parkinson\u2019s disease","volume":"387","author":"Pagano","year":"2022","journal-title":"The New England Journal of Medicine"},{"issue":"1","key":"10.1016\/bs.irn.2026.08.019_bib128","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/s41531-025-01041-9","article-title":"Time-to-event analysis mitigates the impact of symptomatic therapy on therapeutic benefit in Parkinson\u2019s disease trials","volume":"11","author":"Pagano","year":"2025","journal-title":"npj Parkinson\u2019s Disease"},{"issue":"1","key":"10.1016\/bs.irn.2026.08.019_bib129","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/jnnp.54.1.30","article-title":"The absolute number of nerve cells in substantia nigra in normal subjects and in patients with Parkinson\u2019s disease estimated with an unbiased stereological method","volume":"54","author":"Pakkenberg","year":"1991","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"issue":"1","key":"10.1016\/bs.irn.2026.08.019_bib130","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/ana.20321","article-title":"Alpha-synuclein pathology does not predict extrapyramidal symptoms or dementia","volume":"57","author":"Parkkinen","year":"2005","journal-title":"Annals of Neurology"},{"issue":"23","key":"10.1016\/bs.irn.2026.08.019_bib131","article-title":"Development of pyridothiophene compounds for PET imaging of \u03b1-synuclein","volume":"30","author":"Pees","year":"2024","journal-title":"Chemistry"},{"key":"10.1016\/bs.irn.2026.08.019_bib132","doi-asserted-by":"crossref","DOI":"10.1016\/j.parkreldis.2025.108109","article-title":"Relationship between Parkinson\u2019s disease and diabetes mellitus: Evidence from the bench to bedside","volume":"142","author":"Peng","year":"2026","journal-title":"Parkinsonism & Related Disorders"},{"issue":"8","key":"10.1016\/bs.irn.2026.08.019_bib133","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1001\/jamaneurol.2018.0605","article-title":"Anti-tumor necrosis factor therapy and incidence of Parkinson disease among patients with inflammatory bowel disease","volume":"75","author":"Peter","year":"2018","journal-title":"JAMA Neurology"},{"issue":"5321","key":"10.1016\/bs.irn.2026.08.019_bib134","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1126\/science.276.5321.2045","article-title":"Mutation in the alpha-synuclein gene identified in families with Parkinson\u2019s disease","volume":"276","author":"Polymeropoulos","year":"1997","journal-title":"Science (New York, N. Y.)"},{"issue":"6","key":"10.1016\/bs.irn.2026.08.019_bib135","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/mdc3.14055","article-title":"I(123)-FP-CIT (DaTSCAN) SPECT beyond the most common causes of parkinsonism: A systematic review","volume":"11","author":"Quintas","year":"2024","journal-title":"Movement Disorders Clinical Practice"},{"issue":"12","key":"10.1016\/bs.irn.2026.08.019_bib136","article-title":"Antidiabetic agents as antioxidant and anti-inflammatory therapies in neurological and cardiovascular diseases","volume":"14","author":"Raut","year":"2025","journal-title":"Antioxidants (Basel)"},{"issue":"4","key":"10.1016\/bs.irn.2026.08.019_bib137","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.71344","article-title":"Efficacy and safety of glucagon-like peptide 1 receptor agonists in Parkinson disease: A systematic review and meta-analysis","volume":"16","author":"Raza","year":"2026","journal-title":"Brain and Behavior"},{"issue":"100","key":"10.1016\/bs.irn.2026.08.019_bib138","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.arr.2014.01.004","article-title":"Ageing and Parkinson\u2019s disease: Why is advancing age the biggest risk factor?","volume":"14","author":"Reeve","year":"2014","journal-title":"Ageing Research Reviews"},{"key":"10.1016\/bs.irn.2026.08.019_bib139","first-page":"33","article-title":"Clinical utility of DaTscan\u2122 (123I-Ioflupane injection) in the diagnosis of parkinsonian syndromes","volume":"3","author":"Roussakis","year":"2013","journal-title":"Degenerative Neurological and Neuromuscular Diseases"},{"issue":"1","key":"10.1016\/bs.irn.2026.08.019_bib140","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12967-025-07471-6","article-title":"Biomarkers for Lewy body diseases and other alpha-synucleinopathies in biofluids: Current evidence and future directions","volume":"24","author":"Russotto","year":"2025","journal-title":"Journal of Translational Medicine"},{"issue":"12","key":"10.1016\/bs.irn.2026.08.019_bib141","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1002\/mds.27865","article-title":"Exercise increases caudate dopamine release and ventral striatal activation in Parkinson\u2019s disease","volume":"34","author":"Sacheli","year":"2019","journal-title":"Movement Disorders: Official Journal of the Movement Disorder Society"},{"issue":"7","key":"10.1016\/bs.irn.2026.08.019_bib142","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1001\/jamaneurol.2013.114","article-title":"Incidence and pathology of synucleinopathies and tauopathies related to parkinsonism","volume":"70","author":"Savica","year":"2013","journal-title":"JAMA Neurology"},{"issue":"4","key":"10.1016\/bs.irn.2026.08.019_bib143","doi-asserted-by":"crossref","first-page":"667","DOI":"10.3233\/JPD-230390","article-title":"Association of misfolded \u03b1-synuclein derived from neuronal exosomes in blood with Parkinson\u2019s disease diagnosis and duration","volume":"14","author":"Schaeffer","year":"2024","journal-title":"Journal of Parkinson\u2019s Disease"},{"key":"10.1016\/bs.irn.2026.08.019_bib144","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2019.104582","article-title":"Preclinical development of a high affinity \u03b1-synuclein antibody, MEDI1341, that can enter the brain, sequester extracellular \u03b1-synuclein and attenuate \u03b1-synuclein spreading in vivo","volume":"132","author":"Schofield","year":"2019","journal-title":"Neurobiology of Disease"},{"issue":"51","key":"10.1016\/bs.irn.2026.08.019_bib145","article-title":"Brain-targeted liposomes loaded with monoclonal antibodies reduce alpha-synuclein aggregation and improve behavioral symptoms in Parkinson\u2019s disease","volume":"35","author":"Sela","year":"2023","journal-title":"Advanced Materials"},{"issue":"2","key":"10.1016\/bs.irn.2026.08.019_bib146","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1001\/jamaneurol.2016.4547","article-title":"Development of a biochemical diagnosis of Parkinson disease by detection of \u03b1-synuclein misfolded aggregates in cerebrospinal fluid","volume":"74","author":"Shahnawaz","year":"2017","journal-title":"JAMA Neurology"},{"issue":"5","key":"10.1016\/bs.irn.2026.08.019_bib147","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcaf304","article-title":"Phase 1, randomized trials of MEDI1341: Cerebrospinal fluid free \u03b1-synuclein lowered by >50","volume":"7","author":"Shering","year":"2025","journal-title":"Brain Communications"},{"issue":"5","key":"10.1016\/bs.irn.2026.08.019_bib148","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S1474-4422(23)00109-6","article-title":"Assessment of heterogeneity among participants in the Parkinson\u2019s Progression Markers Initiative cohort using \u03b1-synuclein seed amplification: A cross-sectional study","volume":"22","author":"Siderowf","year":"2023","journal-title":"Lancet Neurology"},{"issue":"2","key":"10.1016\/bs.irn.2026.08.019_bib149","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/S1474-4422(23)00405-2","article-title":"A biological definition of neuronal \u03b1-synuclein disease: Towards an integrated staging system for research","volume":"23","author":"Simuni","year":"2024","journal-title":"Lancet Neurology"},{"key":"10.1016\/bs.irn.2026.08.019_bib150","doi-asserted-by":"crossref","DOI":"10.1002\/ana.78250","article-title":"How PPMI enabled the first interventional platform trial to test therapies in participants with early-stage neuronal alpha-synuclein disease","author":"Simuni","year":"2026","journal-title":"Annals of Neurology"},{"issue":"7","key":"10.1016\/bs.irn.2026.08.019_bib151","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1002\/mds.30191","article-title":"Neuronal \u03b1-synuclein disease stage progression over 5\u00a0Years","volume":"40","author":"Simuni","year":"2025","journal-title":"Movement Disorders: Official Journal of the Movement Disorder Society"},{"issue":"4","key":"10.1016\/bs.irn.2026.08.019_bib152","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1002\/mds.28416","article-title":"The rostock international Parkinson\u2019s disease (ROPAD) study: Protocol and initial findings","volume":"36","author":"Skrahina","year":"2021","journal-title":"Movement Disorders: Official Journal of the Movement Disorder Society"},{"issue":"1","key":"10.1016\/bs.irn.2026.08.019_bib153","doi-asserted-by":"crossref","first-page":"6750","DOI":"10.1038\/s41467-023-42305-3","article-title":"The \u03b1-synuclein PET tracer [18F] ACI-12589 distinguishes multiple system atrophy from other neurodegenerative diseases","volume":"14","author":"Smith","year":"2023","journal-title":"Nature Communications"},{"key":"10.1016\/bs.irn.2026.08.019_bib154","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/bs.irn.2020.02.009","article-title":"Status and future directions of clinical trials in Parkinson\u2019s disease","volume":"154","author":"S\u00f6derbom","year":"2020","journal-title":"International Review of Neurobiology"},{"key":"10.1016\/bs.irn.2026.08.019_bib155","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/bs.irn.2020.03.023","article-title":"The NLRP3 inflammasome as a bridge between neuro-inflammation in metabolic and neurodegenerative diseases","volume":"154","author":"S\u00f6derbom","year":"2020","journal-title":"International Review of Neurobiology"},{"issue":"11","key":"10.1016\/bs.irn.2026.08.019_bib156","doi-asserted-by":"crossref","first-page":"6469","DOI":"10.1073\/pnas.95.11.6469","article-title":"Alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson\u2019s disease and dementia with lewy bodies","volume":"95","author":"Spillantini","year":"1998","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"6645","key":"10.1016\/bs.irn.2026.08.019_bib157","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/42166","article-title":"Alpha-synuclein in Lewy bodies","volume":"388","author":"Spillantini","year":"1997","journal-title":"Nature"},{"issue":"9","key":"10.1016\/bs.irn.2026.08.019_bib158","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1012554","article-title":"Enhanced quantitation of pathological \u03b1-synuclein in patient biospecimens by RT-QuIC seed amplification assays","volume":"20","author":"Srivastava","year":"2024","journal-title":"PLoS Pathogens"},{"key":"10.1016\/bs.irn.2026.08.019_bib159","doi-asserted-by":"crossref","DOI":"10.1177\/1877718X261434672","article-title":"Stem cell treatments and Parkinson\u2019s disease: Science and misconceptions","author":"Stamper","year":"2026","journal-title":"Journal of Parkinson\u2019s Disease"},{"key":"10.1016\/bs.irn.2026.08.019_bib160","doi-asserted-by":"crossref","DOI":"10.1177\/17562864251408269","article-title":"Efficacy and safety of glucagon-like peptide-1 receptor agonists in Parkinson\u2019s disease: A systematic review and meta-analysis of randomized placebo-controlled clinical trials","volume":"19","author":"Stefanou","year":"2026","journal-title":"Therapeutic Advances in Neurological Disorders"},{"issue":"5","key":"10.1016\/bs.irn.2026.08.019_bib161","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s00702-025-02882-7","article-title":"Impact of diabetes mellitus type two on incidence and progression of Parkinson\u2019s disease: A systematic review of longitudinal patient cohorts","volume":"132","author":"Stockmann","year":"2025","journal-title":"Journal of Neural Transmission\u00a0(Vienna)"},{"key":"10.1016\/bs.irn.2026.08.019_bib162","article-title":"Projections for prevalence of Parkinson\u2019s disease and its driving factors in 195 countries and territories to 2050: Modelling study of Global Burden of Disease Study 2021","volume":"388","author":"Su","year":"2025","journal-title":"BMJ (Clinical Research ed. )"},{"issue":"2","key":"10.1016\/bs.irn.2026.08.019_bib163","doi-asserted-by":"crossref","first-page":"477","DOI":"10.3233\/JPD-212976","article-title":"Monoamine oxidase-B Inhibitors for the treatment of Parkinson\u2019s disease: Past, present, and future","volume":"12","author":"Tan","year":"2022","journal-title":"Journal of Parkinson\u2019s Disease"},{"issue":"11","key":"10.1016\/bs.irn.2026.08.019_bib164","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1002\/mds.29992","article-title":"Glucagon-like peptide-1 receptor agonists and risk of Parkinson\u2019s disease in patients with type 2 diabetes: A population-based cohort study","volume":"39","author":"Tang","year":"2024","journal-title":"Movement Disorders: Official Journal of the Movement Disorder Society"},{"issue":"3","key":"10.1016\/bs.irn.2026.08.019_bib165","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/ejn.14290","article-title":"Immune system responses in Parkinson\u2019s disease: Early and dynamic","volume":"49","author":"Tansey","year":"2019","journal-title":"The European Journal of Neuroscience"},{"issue":"11","key":"10.1016\/bs.irn.2026.08.019_bib166","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41577-022-00684-6","article-title":"Inflammation and immune dysfunction in Parkinson disease","volume":"22","author":"Tansey","year":"2022","journal-title":"Nature Reviews. Immunology"},{"key":"10.1016\/bs.irn.2026.08.019_bib167","unstructured":"United Neuroscience Ltd. (2025). NCT04075318. Study of UB-312 in healthy participants and Parkinson\u2019s disease patients. Retrieved 20 May 2026 from https:\/\/clinicaltrials.gov\/study\/NCT04075318?term=UB-312&viewType=Card&rank=1."},{"key":"10.1016\/bs.irn.2026.08.019_bib168","unstructured":"University College London. (2016). NCT01971242. Trial of exenatide for Parkinson\u2019s disease (EXENATIDE-PD). Retrieved 25 May 2026 from https:\/\/clinicaltrials.gov\/study\/NCT01971242?cond=Exenatide%20parkinson%27s%20disease&viewType=Card&rank=1."},{"key":"10.1016\/bs.irn.2026.08.019_bib169","unstructured":"University Hospital Tolouse. (2026). NCT03439943. Study to evaluate the effect of lixisenatide in patient with Parkinson\u2019s disease (LixiPark). Retrieved 25 May 2026 from https:\/\/clinicaltrials.gov\/study\/NCT03439943?cond=lixisenatide%20parkinson%27s&term=lixipark&viewType=Card&rank=1."},{"issue":"11","key":"10.1016\/bs.irn.2026.08.019_bib170","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a041645","article-title":"\u03b1-Synuclein in Parkinson\u2019s disease: 12 years later","volume":"14","author":"Vekrellis","year":"2024","journal-title":"Cold Spring Harbor Perspectives in Medicine"},{"issue":"1","key":"10.1016\/bs.irn.2026.08.019_bib171","article-title":"Toward alpha-synuclein seed amplification assay in clinical practice","volume":"17","author":"Verdurand","year":"2025","journal-title":"Alzheimers Dement (Amst)"},{"issue":"10479","key":"10.1016\/bs.irn.2026.08.019_bib172","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S0140-6736(24)02808-3","article-title":"Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson\u2019s disease in the UK: A phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial","volume":"405","author":"Vijiaratnam","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/bs.irn.2026.08.019_bib173","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/2051-5960-1-2","article-title":"The prion hypothesis in Parkinson\u2019s disease: Braak to the future","volume":"1","author":"Visanji","year":"2013","journal-title":"Acta Neuropathologica Communications"},{"issue":"7","key":"10.1016\/bs.irn.2026.08.019_bib174","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S1474-4422(20)30136-8","article-title":"Safety and immunogenicity of the \u03b1-synuclein active immunotherapeutic PD01A in patients with Parkinson\u2019s disease: A randomised, single-blinded, phase 1 trial","volume":"19","author":"Volc","year":"2020","journal-title":"Lancet Neurology"},{"issue":"1","key":"10.1016\/bs.irn.2026.08.019_bib175","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12967-024-06045-2","article-title":"Possible linking and treatment between Parkinson\u2019s disease and inflammatory bowel disease: A study of Mendelian randomization based on gut-brain axis","volume":"23","author":"Wang","year":"2025","journal-title":"Journal of Translational Medicine"},{"issue":"1","key":"10.1016\/bs.irn.2026.08.019_bib176","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s40478-024-01873-1","article-title":"A minimally invasive biomarker for sensitive and accurate diagnosis of Parkinson\u2019s disease","volume":"12","author":"Wang","year":"2024","journal-title":"Acta Neuropathologica Communications"},{"issue":"8","key":"10.1016\/bs.irn.2026.08.019_bib177","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1093\/brain\/awae188","article-title":"Relevance of genetic testing in the gene-targeted trial era: The Rostock Parkinson\u2019s disease study","volume":"147","author":"Westenberger","year":"2024","journal-title":"Brain"},{"issue":"16","key":"10.1016\/bs.irn.2026.08.019_bib178","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.1016\/j.cell.2023.06.004","article-title":"Development of an \u03b1-synuclein positron emission tomography tracer for imaging synucleinopathies","volume":"186","author":"Xiang","year":"2023","journal-title":"Cell"},{"issue":"5","key":"10.1016\/bs.irn.2026.08.019_bib179","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/mds.29363","article-title":"Brain and systemic inflammation in de novo Parkinson\u2019s disease","volume":"38","author":"Yacoubian","year":"2023","journal-title":"Movement Disorders: Official Journal of the Movement Disorder Society"},{"key":"10.1016\/bs.irn.2026.08.019_bib180","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41531-020-0117-1","article-title":"Current and projected future economic burden of Parkinson\u2019s disease in the U.S","volume":"6","author":"Yang","year":"2020","journal-title":"NPJ Parkinson\u2019s Disease"},{"issue":"7","key":"10.1016\/bs.irn.2026.08.019_bib181","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1002\/mds.29016","article-title":"A randomized first-in-human study with UB-312, a UBITh\u00ae \u03b1-synuclein peptide vaccine","volume":"37","author":"Yu","year":"2022","journal-title":"Movement Disorders: Official Journal of the Movement Disorder Society"},{"issue":"3","key":"10.1016\/bs.irn.2026.08.019_bib182","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s13311-013-0187-4","article-title":"Developing therapeutic antibodies for neurodegenerative disease","volume":"10","author":"Yu","year":"2013","journal-title":"Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics"},{"issue":"1","key":"10.1016\/bs.irn.2026.08.019_bib183","doi-asserted-by":"crossref","first-page":"5661","DOI":"10.1038\/s41467-024-49949-9","article-title":"Neuroimaging and fluid biomarkers in Parkinson\u2019s disease in an era of targeted interventions","volume":"15","author":"Zarkali","year":"2024","journal-title":"Nature Communications"},{"issue":"16","key":"10.1016\/bs.irn.2026.08.019_bib184","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26168078","article-title":"The influence of insulin resistance and type 2 diabetes on cognitive decline and dementia in Parkinson\u2019s disease: A systematic review","volume":"26","author":"Zeidan","year":"2025","journal-title":"International Journal of Molecular Sciences"},{"issue":"4","key":"10.1016\/bs.irn.2026.08.019_bib185","doi-asserted-by":"crossref","first-page":"809","DOI":"10.3233\/JPD-230444","article-title":"Patient and public involvement and engagement in the development of a platform clinical trial for Parkinson\u2019s disease: An evaluation protocol","volume":"14","author":"Zeissler","year":"2024","journal-title":"Journal of Parkinson\u2019s Disease"},{"issue":"2","key":"10.1016\/bs.irn.2026.08.019_bib186","doi-asserted-by":"crossref","first-page":"413","DOI":"10.3233\/JPD-191856","article-title":"Is it possible to conduct a multi-arm multi-stage platform trial in Parkinson\u2019s disease: lessons learned from other neurodegenerative disorders and cancer","volume":"10","author":"Zeissler","year":"2020","journal-title":"Journal of Parkinson\u2019s Disease"},{"issue":"1","key":"10.1016\/bs.irn.2026.08.019_bib187","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3892\/etm.2023.12311","article-title":"Relationship among \u03b1\u2011synuclein, aging and inflammation in Parkinson\u2019s disease (review)","volume":"27","author":"Zhang","year":"2024","journal-title":"Experimental and Therapeutic Medicine"},{"issue":"14","key":"10.1016\/bs.irn.2026.08.019_bib188","doi-asserted-by":"crossref","DOI":"10.3390\/cells14141108","article-title":"Discovery of N-(6-Methoxypyridin-3-yl)quinoline-2-amine derivatives for imaging aggregated \u03b1-synuclein in Parkinson\u2019s disease with positron emission tomography","volume":"14","author":"Zhao","year":"2025","journal-title":"Cells"},{"issue":"19","key":"10.1016\/bs.irn.2026.08.019_bib189","doi-asserted-by":"crossref","DOI":"10.3390\/cells14191531","article-title":"Multi-fused S,N-heterocyclic compounds for targeting \u03b1-synuclein aggregates","volume":"14","author":"Zheng","year":"2025","journal-title":"Cells"},{"issue":"12","key":"10.1016\/bs.irn.2026.08.019_bib190","doi-asserted-by":"crossref","first-page":"3949","DOI":"10.1111\/ene.16041","article-title":"Comparison of biospecimens for \u03b1-synuclein seed amplification assays in Parkinson\u2019s disease: A systematic review and network meta-analysis","volume":"30","author":"Zheng","year":"2023","journal-title":"European Journal of Neurology: the Official Journal of the European Federation of Neurological Societies"}],"container-title":["International Review of Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0074774226001194?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0074774226001194?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T11:29:28Z","timestamp":1789990168000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0074774226001194"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"ISBN":["9780443472183"],"references-count":190,"URL":"https:\/\/doi.org\/10.1016\/bs.irn.2026.08.019","relation":{},"ISSN":["0074-7742"],"issn-type":[{"value":"0074-7742","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]}}}